The immunological group contains reactions which occur because of complement abnormalities; an example is the condition hereditary angioneurotic oedema. This is a dominantly inherited disorder and is characterized by recurring attacks of angioneurotic oedema. There is a functional deficiency of the first complement factor inhibitor (C1 INH). The Cl component is present in normal concentrations. Without this C1 inhibitor, C1 activation readily occurs and this results in cleavage products which have kinin activity. It is these products which cause the angio-oedema1.
An acquired form of complement mediated angioneurotic oedema was described in 1972 2 • It was noted to occur in patients with lymphomas. The clinical picture is indistinguishable from the hereditary form, but there is no family history. The biochemical difference is that the C1 component is low as well as the other complement abnormalities found in the hereditary form of the disease. Many ofthese patients have been noted to have an abnormal paraproteinand it is thought to be this which activates and so depletes the complement pathway.
The non-immunological mechanisms for generating angioneurotic oedema are probably brought about by the direct action of drugs on the mast cell membrane'. In this way vaso-active mediators are released which increase capillary permeability. Well known examples of drugs able to do this are radiocontrast media, opiates, azo-dyes and benzoatesl-", It is possible, in view of our patient's lymphoma and abnormal complement levels, that he had the acquired form of angioneurotic oedema. There may also be another explanation in that amongst the 20 constituents of Benylin, there is an azo-dye (Ponceau 4RE124) and a benzoate. Either of these 2 drugs could have precipitated the life-threatening oedema. References at 34 gil (normal 35-45), but other tests of hepatic and renal function were normal. The erythrocyte sedimentation rate was raised to 65 mm/h and immune complexes containing C1q, IgG and IgM were present in the serum. At endoscopy there were many large, discrete ulcers in the transverse and descending colon and linear ulcers in the oesophagus. Histology of these lesions showed non-specific inflammation. A Schilling test was normal, showing that the terminal ileum was not diseased, but xylose absorbtion was reduced (3 h urinary xylose excretion following a 5 g oral dose was 0.53 g (normal > 2.5 g) suggesting that the small intestine was damaged).
A diagnosis of Beheet's disease with oesophageal and colonic involvement was made. Her condition improved slightly with prednisolone 60 mg per day, but her diarrhoea persisted, despite concurrent Behcet's disease is a multisystem disorder which causes gastroenterological symptoms in about half the cases', In most patients these symptoms are minor, transient disturbances of bowel function. A minority of patients develop colitis'' or oesophagitie", the latter being rare. The treatment of the gastroenterological complications of Behcet's disease is controversial. We have recently seen an unusual case of Behcet's disease with colonic and oesophageal involvement which was treated successfully with sulphasalazine and cyclosporin.
Case report
A 61-year-old women presented in 1985 with conjunctivitis, arthritis and myalgia. Her symptoms resolved with non-steroidal anti-inflammatory drugs. Four months later she developed buccal ulceration which healed without therapy. In June'1986 she presented with oro-genital ulceration, folliculitis and bloody diarrhoea. Investigations showed a microcytic anaemia, haemoglobin 9.4 gil (mean corpuscular volume 77 fl) with a low serum iron of 11.3 /tmolll (normal 13-32) and an iron binding capacity of 48/tmolll (normal 45-78). Her albumin was reduced G R Foster MRCP St Charles Hospital, Exmoor Street, London WIO 6DZ codeine phosphate 240 mg/d. The introduction of sulphasalazine coincided with a clinical and serological remission (see Figure 1 ). Two weeks after starting sulphasalazine she developed faecal obstruction. Her medication (apart from prednisolone) was withdrawn and the obstruction was relieved with enemas. Her diarrhoea returned, but ceased when sulphasalazine was reintroduced. She remained in clinical and serological remission (despite a gradual decrease in the dose of prednisolone) until December 1986, when she relapsed. Azathioprine at a maximally tolerated dose of 150 mg per day and an increase in the dose of prednisolone induced a short remission, but her diarrhoea and buccal ulceration returned in January 1987. Cyclosporin A was added to her treatment at a dose of 10 mg/kg, her symptoms improved within 3 days. Cyclosporin was stopped after 6 weeks and she has remained well since that time.
Discussion
The diagnosis of'Behcet's disease is based on clinical criteria because there is no specific diagnostic test. The classification of Mason and Barnes! is widely used and Behcet's disease is diagnosed when any 3 of the major diagnostic criteria are present. According to this system our patient had 4 of the diagnostic criteria for the diagnosis of Behcet's disease (orogenital ulceration, skin lesions and ocular involvement) confirming the diagnosis.
The co-existence of colonic and oesophageal ulcers in Behcet's disease is rare and has been the subject of a small number of case reports", These reports describe severe, symptomatic oesophageal lesions: our patient had minimal dysphagia and gastroscopy showed that the oesophagus was diseased. This suggests that oesophageal involvement in Behcet's disease may be more common than is presently believed.
The treatment of Behcet's colitis is controversial: steroids are the major therapeutic agent, but there is concern that they may provoke colonic perforation-, The role of anti-mitotic drugs has not been determined. Our case confirms previous reports that sulphasalazine may be of value in the treatment of this condition" because on 2 separate occasions the introduction of the drug was associated with improvement.
Cyclosporin A has been shown to be of value in the treatment of ocular Beheet's", To our knowledge it has never been used in the treatment of the colonic complications, but it has been shown to be a useful treatment for refractory Crohn's disease". Our case suggests that it may be of value in the treatment of Beheet's colitis. We describe a patient with autoimmune thyroid disease in whom multiple autoantibodies caused a fluctuating clinical state and interference with hormone assays.
Case report
A 31-year-old male presented in 1982 with lethargy and cold intolerance. On examination he had a small goitre, mild exophthalmos, dry skin, hoarse voice and slow relaxing reflexes. His serum total thyroxine (T4) was 126 nmolll (normal range 50-130nmol/l) and TSH >64mUIL «6 mUlL).
Thyroid microsomal antibodies were positive 1 : 6 500 000. He was treated with thyroxine 150 Ilg daily and became clinically euthyroid although the exophthalmos persisted.
Two years later in 1984, he developed purpura. His platelet count was 20x10 91l and platelet antibodies were positive. He was started on 40 mg per day of'prednisolone with a good response. On decreasing the dose of thyroxine to 50 Ilghe became clinically hypothyroid again and TSH rose to 9.6 mUll although his serum T4 was 117 nmolll. He became euthyroid again on 150 Ilg of thyroxine. Six months later his thrombocytopenia relapsed on prednisolone 10 mg daily and he underwent a splenectomy. One month later he developed tremors, sweating and heat intolerance. He had a tachycardia but no goitre and his exophthalmos was unchanged. His serum free thyroxine <FI'4, Amersham, UK) was > 106 pmolll (8.8-23.0), total T3 8.8 nmolll « 3) and TSH 1 mUll. Thyroxine replacement was stopped but a month later he remained clinically and biochemically hyperthyroid with a serum FT4 > 106 pmolll. His serum FT4 measured by an equilibrium dialysis method was 46.8 pmolll (8.8-23.0) and thyroid binding globulin (TBG) 10 ng/l (7-17). He was treated with carbimazole and 6 months later was clinically
